74 results about "Somatostatin receptor" patented technology

Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I):

[wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.

The invention discloses Al18F-NOTA-PEG6-TATE of a targeted somatostatin receptor and a preparation method and application of Al18F-NOTA-PEG6-TATE. The preparation method of the label includes the steps that a somatostatin derivative TATE and a difunctional chelating agent NOTA are connected through PEG to generate a radiolabelled precursor, then positron nuclide 18F labeling is carried out through a one-pot method, and the 18F labeled somatostatin derivative Al18F-NOTA-PEG6-TATE can be obtained. The method can be carried out in an acetate buffer solution system or an acetonitrile reaction system, and the method has the advantages of being easy and convenient to operate and high in labeling rate and product purity. The prepared positron label of the targeted somatostatin receptor can be applied to preparation of a PET/CT molecular probe or tumor therapy medicine, and provides a novel thought for synthesis of the clinical PET/CT molecular probe.

A novel class of analogs which exhibit both high affinity and selectivity for Neuromedin B and Somatostann receptors are claimed. One example is Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂.

The present invention is directed to imidazolyl derivatives of the formula:

where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors. The derivatives are useful for treating a variety of diseases including acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, cancer, cancer cachexia, hypotension, postprandial hypotension, panic attacks, GH secreting adenomas or TSH secreting adenomas.

Provided is a somatostatin receptor subtype-2 agonist. A compound represented by general formula (I) [wherein each symbol has the same meaning as defined in the description], a salt thereof, an N-oxide thereof or a solvate thereof, or prodrugs of the same, which are low-molecular compounds having potent agonistic activity to somatostatin receptor subtype-2 and, therefore, can be administered in a simpler manner and have high safety and low toxicity, are useful in preventing and/or treating somatostatin-related diseases such as acromegaly and gastrointestinal obstruction.

The present invention relates generally to the use and application of compounds or agents, including somatostatin analogs, with effect on, affinity for, or specificity to SSTR3 and/or SSTR5 somatostatin receptors, particularly in the breast, for the treatment of breast hyperplasia, pre-neoplastic lesions and breast carcinoma and/or prevention or reduction of risk for breast cancer or treatment of breast cancer, including DCIS. The invention also relates to use of somatostatin analog SOM230 in treatment of breast hyperplasia and/or prevention or treatment of breast cancer. The invention includes assays and methods for screening and identifying breast hyperplasia with elevated SSTR3 and/or SSTR5 receptors and for chemotherapy and identifying compounds of use in the invention which are specific for, modulate via, or bind to SSTR3 and/or SSTR5 receptors.

The present invention relates to methods of treating cancers that over-express somatostatin receptors. More specifically, the invention provides a combined therapy in which a combination of Peptide Receptor Radionuclide Therapy (PRRT) and Immuno Oncology therapy (I-O therapy) are administered for the treatment of neuroendocrine tumors.

Novel diagnostic and therapeutic peptides disclosed herein are somatostatin analogs backbone cyclized through metal complexation, and having improved somatostatin receptor subtype affinity and selectivity. These backbone cyclized peptide analogs possess unique and superior properties over other analogs, including chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Pharmaceutical compositions that include these backbone cyclized somatostatin analogs, radiolabelled analogs, reagents for synthesizing same, and methods of using such compositions for diagnostic and therapeutic purposes are also disclosed.

The present invention relates to a delivery carrier including liposomes or nanoparticles for targeting the cells expressed with somatostatin receptor, consisting of a plurality of liposomes that have one phospholipid bilayer coating, one hydrophilic core and a bioactive substance. The bioactive substance is packaged in the hydrophilic core, or embedded in the phospholipid bilayer, or electrically bound with liposomes as a complex, wherein the phospholipid bilayer coating is conjugated with a plurality of molecules in the outer surface. The molecules recognize the somatostatin receptor in the surface of the target cells and induce receptor-mediated endocytosis.

The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonists or antagonists of somatostatin receptors.

[Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one amino acid in a somatostatin or an analog thereof being replaced with a glycosylated amino acid.

The invention provides a somatostatin precursor compound of octreotide, and belongs to the technical field of radioactive drugs and nuclear medicine.The precursor compound is NOTA-TATE, and the structure is shown in the following formula I (the formula is shown in the description). The invention also provides a somatostatin ligand compound of the octreotide, wherein the precursor compound NOTA-TATE is labeled by using radionuclide A to obtain A-NOTA-TATE.The invention also provides a method for preparing the somatostatin precursor compound and the somatostatin ligand compound of the octreotide.The ligand compound obtained by nuclide labeled NOTA-TATE is a colorless transparent liquid injection, has the advantages of simple preparation process, short time-consuming, high labeling rate, stable labeling, good affinity with somatostatin receptors, good targeting for tumor and good imaging effect,can be used for differential diagnosis, staging, accurate localization of focus, treatment andcurative effect monitoring of neuroendocrine tumors, and has good application prospects.

The invention discloses a drug for neuroendocrine tumors and a process thereof, and specifically relates to the field of biopharmaceuticals, wherein the drug includes the following raw materials: cysteamine hydrochloride, Boc2O, TPE-NHS, Boc-SS-NH2, HOOC-PEG5k-NH2, BLG-NCA, NHS, octreotide, 3-aminophenylboric acid and ETO. With phenylborate bonds contained in the drug, micelles can maintain structural stability in blood circulation, thereby protecting an encapsulated drug, reducing drug leakage, and reducing systemic toxic and side effects. When the drug-loaded micelles are gathered in tumor tissues through the EPR effect, octreotide on the surface of the micelles can specifically bind to the overexpressed somatostatin acceptors of neuroendocrine tumor cells, so as to enhance the targetingability of the micelles.

The invention discloses a fusion protein of human somatostatin tetradecapeptide and human serum albumin, comprising a first region homologous with at least 85% sequence of the human somatostatin tetradecapeptide and a second region homologous with at least 85% sequence of the human serum albumin or a second region with partial amino acid sequence of the human serum albumin, wherein the first region homologous with the human somatostatin tetradecapeptide is positioned at the N terminal of the fusion protein, the second region homologous with the human serum albumin is positioned at the C terminal of the fusion protein, and no connecting peptide is added between the first and second regions; or the second region homologous with at least 85% sequence of the human serum albumin is positioned at the N terminal of the fusion protein, the first region homologous with at least 85% sequence of the human somatostatin tetradecapeptide is positioned at the C terminal of the fusion protein, and no connecting peptide is added between the first and second regions. The fusion protein disclosed by the invention prolongs the retention time of the human somatostatin tetradecapeptide molecules in the blood circulation system, and can be used for treating various diseases caused by surplus secretion of growth hormone, for treating diseases caused by endocrine disorder of gastrointestinal tract, for inhibiting growth of tumors expressing somatostatin receptors (SSTRs) and not expressing SSTRs, and for reducing the death rate caused by radiation injury of gastrointestinal tract.